Tailoring Treatment for Patients With HR+/HER2- Metastatic Breast Cancer: Examining the Role of Current and Emerging Endocrine Therapies
Podcast 3 (Hurvitz): Biomarkers for endocrine therapies: What do they mean for clinical practice?
Pre-Test

Questions marked with a * are required

100%

Contact Information

First Name

Last Name

Email Address

Which of the following is a limitation of using ctDNA assays for cancer detection or monitoring?

No mutation data

Reliability at low ctDNA tumor fractions

Lack of standardized definitions

May not track with specific types of cancer

A 56-year-old woman with HR+/HER2- breast cancer experiences disease progression during adjuvant endocrine therapy. She has no significant comorbidities. Circulating tumor DNA testing identifies a PIK3CA mutation. What is the most appropriate treatment option for this patient?

Endocrine therapy (ET) + Everolimus

Endocrine therapy (ET) + trastuzumab + neratinib

Fulvestrant + palbociclib + inavolisib

Chemotherapy

Custom Title